NEW YORK, Dec. 02, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Tyson Foods, Inc. securities (NYSE:TSN) from November 23, 2015 through October 7, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Tyson Foods investors under the federal securities laws.
To join the Tyson Foods class action, go to the firm’s website at http://www.rosenlegal.com/cases-964.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that Tyson Foods had conspired to fix chicken prices. The lawsuit alleges that, as a result, defendants’ statements were materially false and misleading at all relevant times. On September 2, 2016, certain media outlets reported the filing of an antitrust lawsuit against Tyson Foods asserting that it conspired to manipulate the price of broiler-chickens. On October 7, 2016, Pivotal Research reduced its price target and rating for Tyson Foods due to the allegations of the previously reported antitrust lawsuit. The lawsuit claims that investors suffered damages when these details entered the market.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 16, 2016. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-964.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Italy Fines Apple €98.6 Million Over App Store Dominance
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



